{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269534","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.431012+00:00","generated_at":"2026-05-17T00:06:55.733225+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lineage Q3 net loss widens to $29.8M on warrant remeasurement; cash $40.5M","bullets":["Net loss $29.8M ($0.13/sh) vs $3.0M ($0.02) in Q3 2024; includes $26.6M non-cash warrant remeasurement.","Revenue $3.7M, down ~$0.1M YoY; cash $40.5M expected to fund ops into Q2 2027.","Entered collaboration with William Demant Invest for ReSonance (ANP1); up to $12M development funding.","Positive 36-month OpRegen (RG6501) data in dry AMD presented at CTS 2025.","First chronic SCI participant dosed in OPC1 DOSED study; no safety events at 60 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269534","json":"https://secwatch.observer/filing/0001193125-25-269534.json","markdown":"https://secwatch.observer/filing/0001193125-25-269534.md","text":"https://secwatch.observer/filing/0001193125-25-269534.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000119312525269534/0001193125-25-269534-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000119312525269534/lctx-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:06:55.733225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}